Zoetis Inc. (ZTS)

FairStock Score: 72/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Zoetis is the sort of business I like to study: it sells medicines, vaccines and diagnostics for dogs, cats, horses and livestock — recurring needs, scale and switching costs. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported revenue of $2.5B, net income of $691.0M and diluted EPS of $1.65, a 28.00% net margin. Filed annuals show real progress: in fiscal year 2025, the year ended 2025-12-31, revenue was $9.5B and net income $2.7B, up from fiscal year 2023, the year ended 2023-12-31, revenue of $8.5B and net income of $2.3B. FairStock’s Lynch category calls it a STALWART, citing 10.3% annual profit growth and 7.2% revenue growth over five years.

In plain English: Zoetis sells medicines, vaccines and diagnostic tests for pets and farm animals. The business earns high profits and produces plenty of cash, but sales and profits have recently stalled. At the recent price, the stock looks reasonably priced compared with its earnings and cash, though not cheap compared with the value of its net assets.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer